Business Overview

Restorative Biosciences, formerly Cynexus Corporation, is an emerging biotherapeutics enterprise that is dedicated to the development and commercialization of its breakthrough technology to create high performance anti-inflammatory products. The company is an outgrowth of several years of advanced medical research and technology developed in the labs of Dr. Stephen Massia of the Harrington Department of Bioengineering at Arizona State University.

Medical research has been increasingly connecting inflammation to major complex diseases such as cardiovascular disease, cancer and immune disorders. Unfortunately, most of the treatments in the market today treat the overall symptoms of inflammation and do not target the underlying mechanisms by which the inflammation cascade can be effectively halted. Restorative Biosciences' proprietary technology specifically targets the inflammation site without the side effects of conventional treatments.

Restorative Biosciences expects to become a recognized innovator within its targeted applications including Dry Eye disease, allergy induced eye inflammation, cardiovascular disease and cancer. In addition, the core technology is being formulated through a partnership to create anti-inflammatory and anti-infective barriers for ophthalmic medical devices and non-ophthalmic medical device implants.

Latest News:

Restorative Bio accepted to present at Invest Southwest Feb 22, 2007

Dry Eye study completed with Imulan Biotherapeutics